A comparison of fluvoxamine and fluoxetine in the treatment of major depression.

This randomized, double-blind, parallel-group design study of 100 outpatients with major depressive disorder is the first study in the United States to compare the efficacy and tolerability of fluvoxamine (100-150 mg/day) and fluoxetine (20-80 mg/day). After a variable, single-blind, washout period, patients were randomized to receive either fluvoxamine (51 patients) of fluoxetine (49 patients) for 7 weeks. Efficacy was assessed with the 21-item Hamilton Rating Scale for Depression (HAM-D), and Clinical Global Impressions scale for severity and improvement. Eighty-four percent of each treatment group completed the study with each group having a mean score at end point of less than 10. Both groups demonstrated a 60% improvement in HAM-D scores over the 7-week trial. There were no statistically significant differences observed between the two groups on any efficacy parameter. The medications were well tolerated, with only two patients in each group who were terminated because of side effects. There were differences in the side-effect profiles, with fluvoxamine being associated with less nausea than fluoxetine. In summary, fluvoxamine and fluoxetine were equally effective in reducing depressive symptoms, but the two drugs displayed slightly different side-effect profiles.

[1]  W. Inman,et al.  Prescription-Event Monitoring of 10401 Patients Treated with Fluvoxamine , 1994, British Journal of Psychiatry.

[2]  G. Plosker,et al.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. , 1993, Drugs.

[3]  F. Song,et al.  Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. , 1993, BMJ.

[4]  J. Potvin,et al.  Fluoxetine: activating and sedating effects at multiple fixed doses. , 1992 .

[5]  C. Beasley,et al.  Fluoxetine versus trazodone: efficacy and activating-sedating effects. , 1991, The Journal of clinical psychiatry.

[6]  C. Beasley,et al.  High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. , 1991, Journal of clinical psychopharmacology.

[7]  T. Barnes.  A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.

[8]  P. Benfield,et al.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. , 1986, Drugs.

[9]  A. Raskin,et al.  REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF‐REPORT RATINGS OF HOSPITALIZED DEPRESSIVES , 1969, The Journal of nervous and mental disease.

[10]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[11]  M. Hamilton.  The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.

[12]  L. Covi,et al.  Pharmacotherapy of anxiety and depression: Rationale and study design , 1981 .

[13]  L. Covi,et al.  The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. , 1974, Behavioral science.